Avenue Therapeutics

Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.

Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.

Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2

NEW YORK, Aug.  14, 2020  (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the second quarter ended June 30, 2020.

Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.

What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?

Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.30, moving -1.9% from the previous trading session.

Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know

Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.40, moving -1.61% from the previous trading session.

Avenue Therapeutics, Inc. (ATXI) Stock Sinks As Market Gains: What You Should Know

Publication highlights IV tramadol 50 mg demonstrated a statistically significant benefit (p-value < 0.05) over placebo for primary and all key secondary efficacy endpoints Publication highlights IV tramadol 50 mg demonstrated a statistically significant benefit (p-value < 0.05) over placebo for primary and all key secondary efficacy endpoints

Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results

Is  (ATXI) Outperforming Other Medical Stocks This Year?

Is Avenue Therapeutics (ATXI) Stock Outpacing Its Medical Peers This Year?

Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Avenue Therapeutics, Inc. (ATXI) Upgraded to Strong Buy: Here's What You Should Know

As of late, it has definitely been a great time to be an investor in Avenue Therapeutics

Avenue Therapeutics' Shares March Higher, Can It Continue?

Is Avenue Therapeutics (ATXI) Outperforming Other Medical Stocks This Year?

BJ`s Wholesale Club Holdings Inc

Frontline

iClick Interactive Asia Group

ProQR Therapeutics

To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.

5 Low-Beta Stocks to Beat Renewed Coronavirus Concerns

Calix

Channeladvisor

Magic Software Enterprises

Selecting breakout stocks continue to be one of the most popular methods utilized by active investors.

4 Affordable Breakout Stocks for  Stunning Returns

NEW YORK, June  05, 2020  (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the following publications in peer-reviewed journals.

Avenue Therapeutics Announces Publications in Peer-Reviewed Journals

Concert Pharma

MEI Pharma

Minerva Neurosciences

Ocular Therapeutix

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Avenue (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Avenue (ATXI) Stock Stands Out in a Strong Industry

Atlas Air Worldwide

Turtle Beach

Veritone

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

Pick These 5 Stocks With Superb Relative Price Strength

NEW YORK, May  11, 2020  (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2020.

Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

BlackLine

Inseego

MACOM Technology Solutions Holdings

Workiva

Technology Select Sector SPDR Fund

Tech rally is here to stay on solid fundamentals. Bet on stocks that are yet to reclaim their 52-week high levels despite the recent uptrend.

Technology on Solid Footing: 5 Stocks With More Room to Run

Avenue Therapeutics (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Avenue Therapeutics (ATXI) Stock Might be a Great Pick

Cue Biopharma

Gaia

PJT Partners

SpartanNash

A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.

5 Top Small-Cap Stocks Braving Coronavirus Bloodbath

Avenue Therapeutics, Inc. (ATXI) Upgraded to Strong Buy: Here's Why

Avenue Therapeutics Update: Shares A Steal Ahead Of Known PDUFA Action Date

NEW YORK, Feb.  13, 2020  (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Avenue’s New Drug Application (“NDA”) for IV tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting. The FDA set a Prescription Drug User Fee Act (“PDUFA”) goal action date of October 10, 2020.

Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA

Avenue Therapeutics Submits Its NDA; Shares Still Cheap

NEW YORK, Dec.  11, 2019  (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IV tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting.

Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol

News for Avenue Therapeutics Stock (ATXI)